Pharmaceuticals

Jiangsu Quality Horizons Pharmtech Co., Ltd., (abbreviated as QH Holding) is specialized in R&D, manufacturing, sales and marketing of Anthelmintic products.  Currently QH Holding owns three manufacturing sites, i.e.  Changzhou Yabang-QH Pharmachem Co., Ltd.，which been successfully inspected by WHO, EDQM and US FDA,  Lianyungang City Yahui Pharmachem Co., Ltd. and Inner Mongolia Quality Horizons Pharmaceutical Co., Ltd..  The company focuses on Anthelmintic Products，also developed other high value new products，exporting to more than 100 countries. We also offer contract manufacturing services for international big pharmaceutical companies on advanced new drug intermediates and APIs, and maintain long term strategic cooperation relationship with them. We are committed to providing superior quality products, cost effective solutions and innovative technologies to enable customers long-term market success.

Hisun Pharma, founded in 1956, now is the one of the leading pharmaceutical manufactures in China. We are inspected by USFDA, EDQM, HPFB, TGA, APVMA, DCGI, etc.. We have broad portfolio of APIs including Oncology, Cardiovascular, Anti-infectives，Anti-parasitic, etc.

Hebei Shengxue Dacheng Pharmaceuticat Co., Ltd founded in 1997, is a large pharmaceutical company focusing on producing and marketing antibiotics, feed additives and premixes. Our company is state owned and subordinate to China National Nuclear Corporation. We set up two wholly-owned subsidiaries - Hebei Shengxue Dacheng Pharmaceutical (Tangshan) Co., Ltd and Hebei Hongcheng Yaxin Technology Co.,Ltd.

Nantong Jinghua Pharmaceutical Co.,Ltd is a public pharmaceutical company in China that was established in 1957, owning about 302 staffs, located in No. 20, 3 Haibin Road, Yanhai Economic Development Zone, Rudong, Nantong Jiangsu, China. We are appointed as a high-new-technical enterprise by Jiangsu Scientific technological Bureau. As a comprehensive, advanced and innovative GMP company, we focus on manufacture, R&D and sales of APIs, pharmaceutical intermediates. Our company produce Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Flucytosine, Piroxicam, and Propylthiouracil etc., in which the first five products have CEP certificates.

NORTH CHINA PHARMACEUTICAL GROUP SEMISYNTECH CO., LTD is a wholly-owned subsidiary of NCPC, which is specialized in manufacturing and sales of penicillin series products including pharmaceutical intermediates and APIs. The company is located in economic & technical development zone of Liangcun, Shijiazhuang.

Livzon is a comprehensive pharmaceutical enterprise integrating development & research, production and sales of pharmaceutical products, ranking 9 at Top 50 Pharmaceutical companies in China, ranking 8 at Top 10 listed pharmaceutical companies with the highest R&D investment. Livzon Group API Division established June 2015, is dedicated in the R&D, manufacturing and sales of API, including 4 manufacturing sites, Livzon Fuzhou Fuxing, Livzon New North River, Livzon Ningxia and Livzon Syntpharm. Most of the manufacturing sites have been approved by US FDA. And most of the products in regulatory markets have obtained CEP.

Shandong Shengli Bioengineering Co., Ltd is a joint venture built by China Animal Husbandry Industry Co., Ltd and Shandong Shengli Co., Ltd. We are national high-tech enterprise, and mainly producing animal-specific antibiotic API, veterinary preparations and feed additives, such as Tiamulin Fumarate, Enramycin, Bambermycin, Nosiheptide, and Monensin, etc. Shengli strictly follows the current GMP regulations in Europe and the United States, establishes a sound quality management system, and has passed ISO9001, ISO14001, ISO45001 certification, and the US FDA site audit with "0-483". Tiamulin Fumarate API is the first to obtain the EU COS Certificate in China, Enramycin is the first to obtain Production and Sale Certificate domestically. Based in China, with a global business strategy, the company has built a global marketing network.